Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Prior Auth & Step Therapy Coverage …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    Commercial Formulary Prior Authorization and Step Therapy Coverage Criteria

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines HealthPartners commercial pharmacy prior authorization (PA) and step therapy (ST) requirements for medications on the 2026 formulary; applies to prescribers and members under the HealthPartners commercial pharmacy benefit.

    Policy Summary
    PayerHealthPartners
    PolicyCommercial Formulary Prior Authorization and Step Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain and submit product-specific prior authorization criteria and required supporting documentation (e.g., trials of preferred alternatives, specialist attestation, lab results) to request coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+drug entries in excerpt
    multipleentries linking to PA PDFs/URLs
    manyentries reserved for allergy to generic
    severalentries requiring trial/failure of preferred agents
    someopioid-specific attestations required

    Coverage & Prior Authorization Criteria

    General PA/ST conditions (documented across entries)

    Coverage and prior-authorization/step-therapy conditions vary by drug; common conditions across the drug list include:

    Common PA/ST conditions: Examples across listed drugs: reserved for FDA‑approved indications; reserved for patients with a documented allergic reaction to the equivalent generic; reserved for patients with an inadequate response to one or two preferred alternatives (number varies by product); reserved when medical contraindications to preferred alternatives exist; some products require specialist prescribing or documentation in the medical literature demonstrating superiority to preferred options.

    Derived from multiple product entries

    General Step Therapy / PA Criteria

    Covered when meeting product-specific step therapy or prior authorization criteria as stated below:

    General conditions: Member has an inadequate response to the required number of preferred products OR has a documented medical contraindication OR has a documented allergic reaction to the equivalent generic as specified by the product entry.
    Policy Summary
    PayerHealthPartners
    PolicyCommercial Formulary Prior Authorization and Step Therapy Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain and submit product-specific prior authorization criteria and required supporting documentation (e.g., trials of preferred alternatives, specialist attestation, lab results) to request coverage.
    SourceLink
    On This Page
    Coverage & Prior Authorization CriteriaWhat Providers Must DoInitial Therapy / Authorization RulesContinuation / Reauthorization RulesStep Therapy Tables & RulesClinical Thresholds & Coding NotesQuantity & Supply LimitsPrescribing & Site-of-Care RequirementsBackground & RationaleKey Definitions
    inadequate response = as specified per product (commonly 1–2 failed alternatives)

    Some products require external PA documents or specialist involvement.

    Opioid-specific: For long-acting opioids, provider must attest therapy is managed per standard opioid prescribing guidelines and that the patient had an adequate trial (minimum 30 days continuous) of a short‑acting opioid prior to consideration of long‑acting formulations.>= 30 days

    Provider attestation required for long‑acting opioid approvals.

    General coverage condition patterns (C–CY)

    Coverage is product-specific; common covered‑when rules include:

    Reserved for FDA‑approved indications: Covered when used for FDA‑approved indications and when product-specific requirements are met (commonly trial/failure of preferred alternatives or documentation of contraindication).

    Repeated pattern across many entries.

    Documented allergic reaction to generic: Covered when the member has a documented allergic reaction to the equivalent generic or biosimilar, permitting branded product use as specified.documented allergic reaction

    Common brand-exception pathway.

    Specialist prescribing/management: Covered when prescribed by or in consultation with the specified specialist (e.g., cystic fibrosis center for inhaled antibiotics, infectious disease for selected antifungals/antibiotics).

    Some agents require specialist management and renewal documentation.

    CAPLYTA

    CAPLYTA (example product-level criteria):

    CAPLYTA specific criteria: 1) Caplyta is being used for an FDA‑approved indication; AND 2) Prescribed by or in consultation with a behavioral health provider; AND either (a) patient has tried and failed at least 2 formulary alternatives (risperidone, quetiapine, aripiprazole, olanzapine, ziprasidone, lurasidone) OR (b) patient was previously stable on Caplyta.

    From the CAPLYTA entry in the drug list.

    CAYSTON

    CAYSTON (aztreonam inhalation) specific criteria:

    CAYSTON initial approval: 1) Patient has cystic fibrosis with documented Pseudomonas aeruginosa in the lungs; AND 2) Prescribed and managed by specialists from a cystic fibrosis treatment center; AND 3) Quantity limited to one 28‑day package per month.one 28‑day package per month

    Initial approvals provided for 12 months; renewals require CF center visit within last 12 months and documented effectiveness.

    CHOLBAM

    CHOLBAM specific criteria:

    CHOLBAM initial and reauthorization: 1) Prescribed by a specialist; AND 2) Indicated for bile acid synthesis disorders due to single enzyme defects (SEDs) OR adjunctive treatment in peroxisomal disorders with clinical liver manifestations; AND 3) Prescribed at ≤ 15 mg/kg/day (or 17 mg/kg/day in specified situations).dose <= 15 mg/kg/day

    Patient weight required to verify dose; initial authorization 6 months; reauthorization when liver function improves and annually thereafter if effective.

    Not medically necessary / restricted brand

    Examples of explicit not‑medically‑necessary or restricted‑brand stances:

    Deflazacort (brand) NMN rule: Deflazacort (brand) will be considered not medically necessary because there is insufficient evidence of superiority to much less costly alternatives; brand may be reserved only for patients with a documented allergic reaction to the equivalent generic.

    Explicit NMN statement in the formulary entries.

    Dalfampridine ER criteria

    Dalfampridine ER (Ampyra) initial and continuation criteria example:

    Initial approval conditions: Patient has multiple sclerosis; is able to walk 25 feet; neurologist prescriber provides attestation that the patient has difficulty walking; dose not to exceed 10 mg twice daily.dose <= 10 mg twice daily

    Initial authorization limited to 6 months.

    Continuation criteria: Continued approval after 6 months requires documentation of improved ambulation; annual approvals thereafter for sustained positive response.documented ambulation improvement

    Provider documentation required for renewal.

    Topical diclofenac criteria

    Topical diclofenac examples:

    Diclofenac 1.5% topical solution: Reserved for patients who have tried and failed Voltaren 1% topical gel and when significant clinical rationale suggests improved outcomes compared with the preferred gel.failure of Voltaren 1% gel

    Per diclofenac topical entry.

    General step therapy/prior authorization logic

    Products are covered only under the following generalized conditions (applies variably by product):

    Coverage conditions: Covered when the product is used for FDA‑approved indications and the member has had an inadequate response to preferred alternatives OR has medical contraindications to preferred products OR meets product‑specific prior authorization criteria documented in linked PA PDFs.inadequate response to 1–2 preferred products (commonly 2)

    Some products require documentation of benefit in the literature or specialist prescribing.

    EMSAM specific criteria

    EMSAM (selegiline transdermal) high‑step requirement:

    EMSAM pathways: (1) Inadequate response to multiple prior antidepressants: at least three SSRIs AND at least one SSNRI AND at least one other antidepressant (e.g., bupropion, mirtazapine, phenelzine, tranylcypromine); OR (2) Previously stable on EMSAM.specified medication classes and counts

    Exact trial history must be documented.

    Fidaxomicin

    FIDAXOMICIN (DIFICID) coverage conditions:

    Fidaxomicin: 1) Diagnosis of Clostridioides difficile infection; AND 2) Inadequate response or medical contraindication to one or more courses of oral vancomycin; Approvals limited to 10 days.10 days

    Document prior vancomycin therapy and diagnosis.

    Long-acting opioid (fentanyl) criteria

    Long‑acting fentanyl and similar opioid criteria:

    Long-acting fentanyl/LA opioid: Provider must attest therapy is managed per standard opioid prescribing guidelines AND patient had an inadequate response to a recent adequate trial (minimum 30 days continuous) of a short‑acting opioid.>= 30 days

    Attestation required for coverage of long‑acting opioid products.

    Standard authorization criteria

    Standard authorization criteria (typical required elements):

    Standard PA/ST conditions: Member must have documentation of either: (1) documented allergic reaction to the equivalent generic/preferred alternative; OR (2) inadequate response to two preferred alternatives; OR (3) medical contraindication to preferred alternatives; when specified, FDA indication and provider attestations or specialist prescribing are also required.

    Some drugs reference external PA PDFs for full criteria.

    Gattex criteria

    Gattex (teduglutide) coverage specifics:

    Gattex initial approval: Adult patients with short bowel syndrome who are dependent on chronic parenteral nutrition (>= 4 L daily) for at least one year AND evidence of significant functional impairment due to PN dependence. Initial approvals granted for 3 months at doses up to 5 mg daily.>= 4L daily; >= 1 year

    Reauthorizations require documented reduction in parenteral nutrition volume and are provided up to one year.

    General product-level PA and step therapy rules

    General product-level prior authorization and step therapy rules (examples):

    General Step/PA requirements: Approval requires meeting product‑specific prior authorization criteria (linked) OR documented inadequate response to one or more preferred alternatives OR documented medical contraindication or allergy; some products require failure of two preferred alternatives or specialist prescribing.varies by product

    Follow linked PA documents for product-specific details.

    Not medically necessary — deflazacort (brand)

    Exceptions and explicit not‑medically‑necessary stance:

    Deflazacort brand NMN: Brand deflazacort will be considered not medically necessary due to insufficient evidence of superiority to much less costly alternatives; brand may be reserved only when documented allergic reaction to the equivalent generic exists.

    Explicit statement in the formulary.

    Lanreotide (Somatuline Depot) approval conditions

    Lanreotide (Somatuline Depot) approval conditions:

    Lanreotide initial approval: Reserved for patients for whom surgery is not an option or not curative, and who have failed one somatostatin analogue; initial approvals provided for 6 months with annual approvals for responders thereafter.initial 6 months

    Product-specific duration and failure requirement.

    General Step Therapy / Prior Authorization

    General step therapy / prior authorization pattern applied to many products:

    General step/PA requirement: Coverage typically reserved for FDA‑approved indications AND one of: inadequate response to two preferred alternatives OR medical contraindication to preferred alternatives; some products specify different counts or link to external PA documents.two failed preferred alternatives (common)

    Per repeated entries across the formulary.

    Long‑acting opioid PA requirement

    Long‑acting opioid prior authorization requirement (planwide pattern):

    Long‑acting opioid attestation: Provider must attest therapy is managed per standard opioid prescribing guidelines AND there is documentation of an inadequate response to a recent adequate trial (minimum 30 days continuous) of a short‑acting opioid.>=30 days

    Applies to long‑acting opioid products listed in the formulary.

    General product-specific coverage criteria (examples)

    Common product-specific coverage criteria patterns (examples):

    Inadequate response to preferred therapies: Patient has an inadequate response to two preferred alternatives (or other specified number) or has medical contraindications to their use.

    Common requirement across many entries.

    Allergy/brand exception: Patient has a documented allergic reaction to the equivalent generic or biosimilar where brand is reserved for such cases.documented allergic reaction

    Repeated pathway across the formulary.

    FDA‑approved indication and specialist involvement: Product reserved for FDA‑approved indications and may require specialist prescribing or additional documentation per linked PA criteria.

    Follow linked PA documents for full product criteria.

    Nexletol/Nexlizet lipid criteria: Reserved when LDL >= 70 mg/dL and there is inadequate response or contraindication to high‑intensity statins and ezetimibe; approvals given for one year with reauthorization requiring LDL reduction documentation.LDL >= 70 mg/dL

    Per Nexletol/Nexlizet entries.

    Nuzyra (example specialty antibiotic): Reserved for FDA‑approved indications, prescribing by or in consultation with Infectious Disease providers, and for patients with inadequate response to standard treatments; culture and sensitivity results required.

    Per Nuzyra entry.

    General Step Therapy / Prior Authorization criteria

    General Step Therapy / Prior Authorization criteria (summary):

    General ST requirements: Coverage requires meeting product‑specific prior authorization criteria (linked) OR meeting reserved conditions such as documented allergic reaction to equivalent generic, inadequate response to specified preferred alternatives (commonly two), or medical contraindication to preferred therapies.

    See individual product link for full criteria; some products require provider attestation or specialty prescriber.

    General step therapy/prior authorization criteria (P–R list)

    Common step therapy/prior authorization patterns in P–R segment:

    Standard step therapy rule: Covered when ALL of the following are met: (1) FDA‑approved indication where required; (2) documentation of inadequate response to two preferred alternatives OR documentation of medical contraindication/allergy to preferred alternatives; (3) provider supplies supporting documentation or follows the referenced PA form/page.inadequate response to two preferred alternatives

    Many entries reference external PA PDFs or pages for product‑specific details.

    Pulmozyme (site-specific coverage conditions)

    Pulmozyme (dornase alfa) site‑specific coverage conditions:

    Pulmozyme specific: Reserved for cystic fibrosis patients when prescribed and managed by specialists from a cystic fibrosis treatment center; initial approvals for 12 months and annual renewals require documentation of a center visit within the prior 12 months and evidence of effectiveness.annual specialist visit documented

    Site‑of‑care and renewal requirements noted.

    Rebif (MS biologic) criteria

    Rebif (interferon beta‑1a) criteria (MS biologic example):

    Rebif/Rebif RebidoSe: Reserved for patients with an inadequate response to Avonex AND Plegridy, OR with medical contraindications to their use.inadequate response to Avonex AND Plegridy

    Per Rebif entries in the formulary.

    General prior authorization and step therapy logic (R–S excerpt)

    General prior authorization and step therapy logic (R–S excerpt):

    General PA rules: Products are covered only when one of the following applies: (1) documented allergic reaction to the equivalent generic; OR (2) inadequate response to one or two preferred alternatives as specified; OR (3) use is within FDA‑approved indications and any specialist/prescriber requirements are met per linked PA documents.

    Specific counts, specialty requirements and timeframes are product‑specific and detailed in linked PA PDFs.

    General coverage criteria patterns (partial)

    General coverage patterns (partial) — recurring authorization conditions:

    Common authorization requirements: 1) FDA‑approved indication when specified; 2) documented trial and failure or intolerance to one or more preferred alternatives (commonly 1–2); 3) when applicable, documentation of diagnostic test/results or specialist management (e.g., inhaled tobramycin requires Pseudomonas documentation and CF center management); 4) documented allergic reaction to equivalent generic when that pathway is specified; 5) provider attestations for opioid management when required.

    Product‑level PA PDFs may add additional, specific criteria.

    Initial coverage and PA trigger conditions

    Initial coverage and PA trigger conditions (examples):

    General reserved-use: Medication is reserved for patients with an inadequate response to preferred products or with medical contraindications to preferred products; many entries require trials of 1–2 preferred alternatives.

    Some entries specify different counts (e.g., three NSAIDs) or require literature support.

    Allergy/brand-exception: Coverage is allowed when there is a documented allergic reaction to the equivalent generic (brand exception pathway).documented allergic reaction

    Provider documentation required.

    Opioid-specific requirements: For tramadol ER and certain IR opioids: provider attestation of opioid guideline management, documented adequate trial of IR formulation (minimum 30 days for tramadol IR), age restrictions where specified, and IR new‑user supply limits (7‑day first fill; 14‑day total per episode) apply.30 days for tramadol IR trial; 7/14 day supply limits for IR opioids

    Failure to meet these conditions requires PA or may result in denial.

    Prescriber specialty criteria

    Prescriber specialty requirements (examples):

    Specialty prescribing: Some agents are reserved for prescribing by or in consultation with specialty providers (infectious disease, transplant, neurology, oncology, gastroenterology, cystic fibrosis centers).

    Specialty involvement and documentation often required for approval and renewals.

    Drug-specific multi-criteria example

    Drug-specific multi‑criteria example (Viberzi):

    Viberzi (eluxadoline) criteria: Reserved when all are met: (1) Prescribing by gastroenterology; (2) diagnosis of IBS‑D; (3) trial and failure of conventional therapies including loperamide or diphenoxylate/atropine, a TCA, and antispasmodics if pain present; (4) symptoms cause significant disability. Initial approvals limited to one month; one‑year continuation requires significant positive response.initial 1 month

    Multi‑item indication‑specific step/diagnostic criteria.

    General Step Therapy / Prior Authorization criteria (W–Z excerpt)

    General W–Z step therapy / prior authorization criteria (summary):

    General step therapy conditions: Patient has an FDA‑approved indication when specified AND has had an inadequate response to two preferred alternatives (unless product‑specific language indicates otherwise) OR has medical contraindication to preferred alternatives; documentation of clinical benefit over preferred alternatives is required for select products.inadequate response to 2 preferred alternatives

    Some products specify variant rules (e.g., different counts or specialist requirements).

    Opioid attestation

    Opioid attestation requirement (planwide pattern):

    Opioid attestation requirement: Provider must attest therapy is managed per standard opioid prescribing guidelines and that the patient had an adequate recent trial (minimum 30 days continuous) with a short‑acting opioid prior to initiating long‑acting opioid therapy.30 days

    Applies where product text explicitly references long‑acting opioid requirements.

    Generic allergy exception

    Allergy / generic substitution exceptions:

    Allergic reaction to generic: Coverage reserved for patients with a documented allergic reaction to the equivalent generic (applies across multiple products).documented allergic reaction

    Provider documentation required for brand exception approvals.

    Examples of products listed as not medically necessary in the policy reflect explicit determinations based on insufficient evidence of superiority to less costly alternatives. For instance, Agamree is identified as not medically necessary because clinical evidence does not demonstrate advantage over lower‑cost options; such NMN designations are applied when the document-level criteria indicate lack of supportive evidence for the branded product versus available alternatives.

    Many product entries are limited to FDA‑approved indications or otherwise reference an external prior authorization (PA) criteria document that providers must follow. The policy repeatedly points to product‑specific HealthPartners PA webpages or PDFs (links provided inline) as the definitive source of detailed PA requirements and exclusions; approval depends on satisfying those external criteria.

    CAYSTON (aztreonam inhalation) coverage is restricted: it is reserved for patients with cystic fibrosis who have documented Pseudomonas aeruginosa in the lungs, must be prescribed and managed by specialists from a cystic fibrosis treatment center, and is quantity‑limited to one 28‑day package per month. Initial approval periods and renewal documentation (CF center visit within the last 12 months and demonstrated effectiveness) are required as specified in the PA guidance.

    The branded formulation of deflazacort is designated not medically necessary in this policy because the document states there is insufficient evidence that the brand offers superiority compared with much less costly alternatives; the brand may only be considered when a member has a documented allergic reaction to the equivalent generic.

    Several branded products are explicitly reserved for use only when there is a documented allergic reaction to the equivalent generic or when literature demonstrates clinical benefit over preferred alternatives. The policy flags brand‑only coverage pathways when an allergic‑to‑generic exception is required and otherwise reserves brand use pending appropriate documentation.

    Prior authorization and step therapy prerequisites are applied widely: non‑preferred or branded products are typically covered only when the member has had an inadequate response to one or two preferred alternatives, or when there is a documented medical contraindication or documented allergic reaction to the equivalent generic. Some products require additional documentation or provider attestations per the referenced PA criteria.

    The policy restates that certain branded products will be considered not medically necessary absent a documented allergic reaction to the generic equivalent (for example, branded deflazacort/EMFLAZA). Where a brand is NMN, coverage may only be allowed if the PA documentation supports a generic allergy exception.

    Some product entries are limited to specific patient populations. For example, low‑dose liraglutide 0.6 mg is reserved for members with type 2 diabetes, and other entries impose age, weight, or device‑use restrictions as part of the coverage conditions described in the policy.

    For certain agents the policy directs prescribers to stop use or to consult a disease‑specific policy: for example, guidance on Ocaliva directs health care professionals to discontinue prescribing Ocaliva and to see the Primary Biliary Cholangitis policy for further information; the PA entry includes this clinical advisory rather than routine PA approval language.

    Similarly, the document includes a clinical advisory for Oxbryta stating health care professionals should stop prescribing the product and that patients should consult their health care professional about treatment changes; such advisories are noted alongside PA routing where applicable.

    The policy records that Relyvrio is not eligible for coverage because it has been withdrawn from the market; requests for a withdrawn product will be denied. Relatedly, several entries explicitly limit coverage to FDA‑approved indications or to narrow patient groups.

    Many entries specify coverage only for FDA‑approved indications and add step/failure requirements or specialist prescriber conditions. When the policy states a product is reserved for FDA‑approved uses, off‑label use is generally not covered unless the linked product‑specific PA document explicitly allows it.

    Narrow eligibility examples recur throughout the listing: common scenarios include products reserved for patients who have failed defined numbers of preferred agents (commonly two), products restricted to specific diagnoses or age groups, and products that require specialist prescribing or documented diagnostic test results to meet PA criteria.

    Vistogard (uridine triacetate) approvals are limited to approved emergency uses after fluorouracil/capecitabine overdose or specific early‑onset, severe toxicities per the FDA regimen; the policy explicitly states that approvals will not be granted for non‑emergent treatment of adverse reactions because this may diminish efficacy.

    Where a combination product contains multiple active ingredients that can be used separately, the policy often requires a prior trial of the individual active ingredients given separately before authorizing the combination product. This step‑through approach applies when the PA text specifies trying individual components (or preferred formulations) prior to coverage of the listed product.

    The policy lists Agamree as not medically necessary because the document indicates insufficient evidence that the product is superior to less costly alternatives; this rationale underlies NMN determinations for select branded agents when comparative effectiveness is not established.

    Brand products that are reserved for allergy or failure exceptions are not covered when those exceptions are not documented. The policy consistently states branded product use without evidence of a documented allergic reaction to the equivalent generic or without meeting step therapy failure criteria will not meet PA approval.

    This document reiterates that branded deflazacort is considered not medically necessary because of insufficient evidence of superiority; brand coverage is limited to documented allergy to generic equivalents.

    The policy specifically names EMFLAZA (brand deflazacort) as not medically necessary under standard formulary review because evidence does not demonstrate superiority relative to less costly alternatives; brand exceptions require documented allergy to generic.

    The policy repeats the NMN stance for branded deflazacort formulations: absent a documented allergic reaction to the equivalent generic, branded deflazacort will be considered not medically necessary and not eligible for coverage.

    Vistogard PA language includes nuance: coverage is reserved for specific emergent uses (approved dosing/regimen) and for life‑threatening toxicities within defined time windows; non‑emergent uses for chemotherapy adverse reactions are explicitly not approved and therefore are not eligible for routine PA coverage.

    Where clinically appropriate, the policy requires a prior trial of the active ingredients administered separately before approving a combination or branded product. This requirement is applied when the PA text specifies trying individual components or preferred dosage forms first, with documentation of inadequate response or contraindication needed to support progression to the requested product.

    What Providers Must Do

    Prior Authorization

    Prior authorization required

    Medications listed on the HealthPartners commercial drug list require prior authorization; coverage will not be provided unless the product-specific PA criteria are met and PA approval is obtained.

    Prior Authorization

    Follow referenced PA criteria

    Follow the product-specific HealthPartners prior authorization criteria or linked PA PDFs/coverage pages cited in each drug entry; approvals depend on satisfying those external criteria.

    Prior Authorization

    Opioid attestation requirement

    For long-acting opioids and tramadol ER, the provider must attest that therapy is being managed per standard opioid prescribing guidelines; lack of this attestation may prevent approval.

    • Attestation must confirm opioid guideline–based management.
    Prior Authorization

    Prior authorization requirement (general)

    Many listed products are reserved for FDA‑approved indications or require documented failure of preferred alternatives, documented allergy to an equivalent generic, or specialist prescribing per the product-specific PA language.

    Prior Authorization

    Long-acting opioid attestation

    Long‑acting opioid requests require prior authorization plus a provider attestation that therapy is managed per standard opioid prescribing guidelines and evidence of an adequate recent trial (minimum 30 days continuous) with a short‑acting opioid.

    • Adequate short‑acting opioid trial defined as minimum 30 days continuous use.
    Prior Authorization

    Refer to HP public coverage criteria

    Some products (for example, CRYSVITA) direct providers to the HealthPartners public coverage criteria webpages or linked PA PDFs; providers must consult and meet those external criteria for approval.

    Prior Authorization

    PA for generic allergy or failure of preferred alternatives

    When a product is reserved for use only with documented allergic reaction to the equivalent generic, providers must supply documentation of the allergic reaction; absence of this documentation may result in denial.

    • Brand use permitted only when documented allergic reaction to generic is present per the product entry.
    Prior Authorization

    Prior authorization required for listed products

    Prior authorization is required for the many listed products; follow the product-specific PA criteria or linked PDFs for the detailed conditions that must be met for approval.

    Prior Authorization

    General prior authorization requirements

    Providers must meet general PA requirements across many entries, which commonly include documentation of allergic reaction to equivalent generic, inadequate response to preferred alternatives (commonly two), or a documented medical contraindication.

    Prior Authorization

    Prior Authorization required for listed products

    Prior authorization is required for the listed products; consult the HealthPartners product-specific PA criteria cited in the drug list entries for approval requirements.

    Prior Authorization

    Prior authorization required for listed products

    Many products require prior authorization and may link to external PA criteria documents; PA is often reserved for FDA‑approved indications when the member has failed preferred alternatives or has contraindications.

    Prior Authorization

    Prior authorization required for listed drugs

    Many listed drugs require prior authorization and are reserved for patients with inadequate response to preferred alternatives, documented allergic reactions to generics/biosimilars, or other specified conditions; see linked PA webpages for full criteria.

    Prior Authorization

    Long-acting opioid PA requirement

    Long‑acting opioids require prior authorization and a provider attestation confirming guideline-based management plus documentation of an adequate recent trial (minimum 30 days continuous) of a short‑acting opioid; missing the attestation or trial evidence may result in denial.

    • Attestation and documentation of ≥30 days continuous short‑acting opioid trial required.
    Prior Authorization

    Prior authorization required for listed products

    Prior authorization is required for the listed products; many entries include links to product‑specific PA criteria pages or PDFs that providers must follow.

    Prior Authorization

    Prior authorization required

    Prior authorization is required; many listed products are reserved for patients who have failed preferred alternatives or who meet other specified PA conditions—follow the linked PA criteria for product-level details.

    Prior Authorization

    Prior authorization required for many R–S products

    Many R–S section products require prior authorization; criteria vary by product and commonly include failure of preferred alternatives, documented allergy to generic, or referenced external PA PDFs.

    Prior Authorization

    PA for FDA-approved indications with step/failure requirements

    Some products are reserved for FDA‑approved indications and require documented inadequate response to preferred alternatives or documented contraindications as specified in the product PA language.

    Prior Authorization

    Prior authorization required for listed products

    Many listed products require prior authorization with product-specific criteria; providers must supply the documentation specified in the linked PA documents for approval.

    Prior Authorization

    Tramadol ER and general reserved-use PA

    Tramadol ER requires prior authorization with a provider attestation that therapy is managed per opioid prescribing guidelines and documentation of an adequate prior trial (minimum 30 days continuous) of tramadol immediate release; age and quantity limits also apply per the entry.

    • Tramadol ER: attestation + ≥30 days continuous trial of tramadol IR; reserved for adults and children ≥12.
    Prior Authorization

    External PA document references

    Many entries reference external prior authorization PDFs or product-specific PA forms/links; providers must follow those external documents and supply required documentation as specified.

    Prior Authorization

    Prior authorization required

    Prior authorization is required for the products listed; consult the product entries and linked PA criteria for the specific conditions that must be satisfied for coverage.

    Step Therapy

    Step therapy requirement

    Providers must document trials of required preferred alternatives (step therapy) before requesting coverage; if alternatives have not been tried, the provider must request PA and supply documentation of trials or contraindications.

    • Step therapy requires trying one or more other medicines first; approval requires documentation of those trials or exceptions.
    Step Therapy

    General step therapy rule

    Step therapy commonly reserves non‑preferred products for patients with an inadequate response to one or two preferred products, or for those with documented allergies or medical contraindications; follow product-specific step requirements.

    Step Therapy

    Step therapy / trial/failure requirements

    Numerous products are reserved for patients who have tried and failed specified numbers of preferred alternatives (commonly one or two); providers must document the required trials and failures in the PA request.

    • Some entries require documentation in the medical literature when claiming clinical benefit over preferred alternatives.
    Step Therapy

    Step therapy general rule

    Coverage of many branded products is contingent on documented inadequate response to one or more preferred alternatives (often two) or a documented contraindication/allergy; providers must document trials/failures as specified.

    Step Therapy

    Multiple drugs subject to step therapy

    Multiple drugs are subject to step therapy requiring trial/failure of one or two preferred products (commonly two) before non‑preferred product approval; providers must document those trials or provide medical contraindication/allergy evidence.

    Step Therapy

    PA for FDA-approved indications with step/failure requirements

    Step therapy typically requires trial and inadequate response to two preferred alternatives (or one for some products) prior to approval of a non‑preferred agent; providers must document the specific number of failed alternatives per product entry.

    Step Therapy

    General step therapy rule

    Step therapy rules commonly require trial and inadequate response to one or more preferred alternatives (sometimes two) or documented contraindication/allergy before approval of the listed product; providers must provide that documentation.

    Step Therapy

    Step therapy: failure of preferred alternatives

    Step therapy typically requires failure/inadequate response to two preferred alternatives (or more where specified); for some products (e.g., EMSAM) documented trials may be more extensive—providers must supply the exact trial history.

    • EMSAM requires failure of multiple antidepressants (at least three SSRIs, one SSNRI, and one other antidepressant) unless previously stable.
    Step Therapy

    Step therapy: inadequate response to preferred alternatives

    Step therapy frequently requires documenting inadequate response to two preferred alternatives; providers must either document those trials or provide evidence of medical contraindication or allergy as specified per product.

    Step Therapy

    Step therapy requirement

    Step therapy is applied broadly across many drugs; providers must document prior trials or contraindications as specified or follow linked PA criteria when requesting authorization.

    Step Therapy

    Step therapy failure requirements

    Step therapy commonly requires trial and inadequate response to one or two preferred alternatives prior to coverage of non‑preferred products; documentation of those trials must be included in the PA.

    Step Therapy

    Step therapy trial/failure requirements

    Step therapy trial/failure requirements include trials of preferred agents (often one or two alternatives) before non‑preferred products are approved; some entries specify what constitutes treatment failure and may require diagnostic evidence.

    • Example: Talicia requires test-confirmed treatment failure per its criteria.
    Step Therapy

    General step therapy rule

    Step therapy is broadly applied: many drugs are reserved for patients with inadequate response to one or two preferred alternatives or documented contraindications/allergies; providers must document prior trials or exceptions.

    Step Therapy

    Step therapy rule

    Step therapy generally requires failure/inadequate response to two preferred alternatives prior to coverage of the non‑preferred product, unless product-specific language indicates otherwise; providers must document those failures or contraindications.

    Documentation Required

    External PA criteria documentation

    Some product entries reference external prior authorization criteria documents; providers must consult and satisfy those external PA documents and include required evidence with the PA request.

    Documentation Required

    Required supporting documentation

    Medical documentation must be provided to show prior inadequate response to preferred products or medical contraindications/allergies; some products additionally require literature evidence of clinical benefit or provider attestations.

    • Documentation of prior trials/failures or contraindications is required per product-specific criteria.
    Documentation Required

    CHOLBAM dosing and follow-up documentation

    CHOLBAM requires patient weight to verify dosing; initial authorizations are for six months and reauthorization requires improvement in liver function and annual demonstration of efficacy.

    • Dose verification via patient weight is required.
    • Initial authorization 6 months; reauthorization based on liver function improvement.
    Documentation Required

    CAYSTON renewal documentation

    CAYSTON renewals require documentation that the patient has been seen within the last 12 months at the cystic fibrosis treatment center and that the medication is effective; initial approvals are provided for 12 months and quantity limited to one 28-day package per month.

    • Prescribed/managed by CF treatment center specialists.
    • Renewal: CF center visit within last 12 months + effectiveness documentation.
    Documentation Required

    Ophthalmic cystinosis documentation

    For cystinosis ophthalmic products (CYSTADROPS, CYSTARAN) initial approvals are for three months and renewals require documentation of clinical treatment effect, such as slit‑lamp exam notes.

    • Initial approvals: 3 months; renewals require clinical treatment-effect documentation.
    Documentation Required

    Topical diclofenac documentation

    Diclofenac 1.5% topical solution requires prior failure of Voltaren 1% topical gel and a significant clinical rationale or literature support showing improved outcomes over the preferred product.

    • Prior failure of Voltaren 1% gel required.
    Documentation Required

    Documentation of superiority required when reserved for allergy

    When a branded product is reserved due to allergy to the generic, providers must document in the medical record the allergic reaction to the equivalent generic; documentation of superiority in the literature may also be required for some reserved uses.

    • Documentation of allergic reaction to equivalent generic required when specified.
    • Literature documenting clinical benefit may be required for some products.
    Documentation Required

    Gattex documentation

    Gattex initial approvals granted for three months require documentation of parenteral nutrition dependence (≥4 L daily for at least one year); reauthorization requires demonstration of reduction in parenteral nutrition volume.

    • Parenteral nutrition dependence threshold: ≥4 L daily and ≥1 year.
    • Reauthorization requires documented reduction in parenteral nutrition volume.
    Documentation Required

    Follow external PA criteria

    Follow the external product‑specific PA criteria pages or PDFs linked in many drug entries; providers must supply the documentation specified in those external documents for PA approval.

    Documentation Required

    Opioid attestation specifics

    Provider attestation is required for long‑acting opioids confirming management per standard opioid prescribing guidelines and documentation of an inadequate response to a recent adequate short‑acting opioid trial (minimum 30 days); include attestation and trial details in the PA.

    • Attestation should document guideline‑based management and the ≥30‑day short‑acting opioid trial.
    Documentation Required

    Clinical documentation and test results

    Clinical documentation and test results (e.g., culture and sensitivity for Nuzyra, HCV genotype/viral load for Pegasys) must be provided when required by product-specific PA criteria.

    • Provide culture/sensitivity, genotype, viral load, or other test results when specified by product PA.
    Documentation Required

    Nexletol/Nexlizet LDL documentation

    For Nexletol/Nexlizet approvals, providers must document baseline LDL ≥ 70 mg/dL and inadequate response or contraindication to high‑intensity statins and ezetimibe; reauthorizations require documentation of LDL reduction per provider attestation.

    • Baseline LDL ≥ 70 mg/dL required.
    • Documentation of prior statin/ezetimibe therapy failure or contraindication.
    Documentation Required

    Required supporting documentation for specialty agents

    Providers must supply required supporting documentation for specialty agents (prior trials, allergic reactions to preferred generics, specialist management) as specified in product PA entries; missing documentation may lead to denial.

    • Specialist management/annual visits and effectiveness documentation required for some inhaled cystic fibrosis agents.
    Documentation Required

    Follow linked PA documents for required documentation

    When external PA PDFs are linked, follow those documents and provide the documentation they specify (e.g., prior trial/failure, specialty prescriber, diagnosis, lab results) when submitting the PA request.

    Documentation Required

    Tobramycin inhalation documentation

    For inhaled tobramycin formulations in cystic fibrosis, providers must document Pseudomonas aeruginosa in the lungs, specialist prescription/management by a CF treatment center, and quantity limited to one 56‑count carton per 56 days; renewals require annual CF center visit documentation and effectiveness.

    • Document Pseudomonas aeruginosa infection and CF center specialist management.
    • Quantity limit: one 56‑count carton per 56 days; renewals require annual visit and effectiveness documentation.
    Documentation Required

    Required documentation for PA

    Provider attestation documenting management per opioid prescribing guidelines and documentation of an adequate trial of preferred dosage forms (e.g., 30 days for tramadol IR) or documented contraindication/allergy to preferred generics is required for opioid and other PA requests.

    • IR opioid new users: 7‑day first fill; 14‑day total per episode unless PA obtained with attestation and risk assessment.
    Documentation Required

    Required supporting documentation

    Clinical documentation should demonstrate inadequate response to preferred alternatives (commonly two) or medical contraindication; literature documenting clinical benefit over preferred alternatives is required for some products.

    Documentation Required

    Opioid attestation

    For long‑acting opioids, provider attestation that therapy is managed per standard opioid prescribing guidelines and that the patient had an adequate recent trial (minimum 30 days continuous) of a short‑acting opioid is required; include this attestation with the PA request.

    • Adequate trial defined as minimum 30 days continuous short‑acting opioid use.
    Denial Risk

    Prior authorization required for coverage

    Coverage requires meeting HealthPartners prior authorization criteria for medicines listed on the drug list; lack of PA approval will prevent coverage.

    Denial Risk

    Failure to meet step therapy prerequisites

    Requests may be denied if the patient has not had the required inadequate response to preferred alternatives or lacks documentation of medical contraindication or allergy as specified in the product PA.

    • Failure to document required step therapy trials is a common reason for denial.
    Denial Risk

    CAYSTON approval restrictions

    CAYSTON approvals are limited to cystic fibrosis patients with Pseudomonas aeruginosa, prescribed and managed by CF treatment center specialists, quantity limited to one 28‑day package per month; initial approval 12 months and renewals require documentation of CF center visit and effectiveness—requests outside these conditions may be denied.

    • Initial approvals: 12 months; annual renewal requires CF center visit within last 12 months and effectiveness documentation.
    Denial Risk

    Not covered without documented allergy to generic

    Deflazacort brand is considered not medically necessary due to insufficient evidence of superiority; coverage is reserved only for patients with a documented allergic reaction to the equivalent generic.

    • Brand considered not medically necessary except when documented generic allergy exists.
    Denial Risk

    Dalfampridine ER authorization requirements

    Dalfampridine ER (Ampyra) approvals require neurologist prescribing, baseline walking ability (able to walk 25 feet), physician attestation of walking difficulty, dose limit 10 mg twice daily, initial approval for six months, and continuation requires documented ambulation improvement.

    • Neurologist prescriber required.
    • Initial approval 6 months; continuation requires documented ambulation improvement.
    Denial Risk

    Failure to document trials of required preferred alternatives

    Failure to document trials of required preferred alternatives (for example, EMSAM requires inadequate response to at least three SSRIs AND one SSNRI AND one other antidepressant) may trigger denial.

    • Exact trial counts must be documented per product (EMSAM example shown).
    Denial Risk

    Long-acting opioid attestation and trial

    Long‑acting opioids require provider attestation of guideline‑based management and an adequate recent trial (minimum 30 days continuous) with a short‑acting opioid; missing attestation or trial evidence may result in denial.

    Denial Risk

    Common triggers for denial

    Common triggers for denial include lack of documentation of allergic reaction to the equivalent generic, no documented inadequate response to required number of preferred alternatives (commonly two), or missing specialist/diagnostic evidence when required.

    • Examples: missing Pseudomonas documentation for inhaled tobramycin; no documented trials for step therapy.
    Denial Risk

    Not medically necessary — deflazacort (brand)

    Deflazacort (brand/EMFLAZA) will be considered not medically necessary due to insufficient evidence of superiority; PA requests for brand without documented generic allergy may be denied.

    Denial Risk

    Failure to meet step therapy trials

    Requests may be denied if the member has not tried and failed the required number of preferred alternatives (commonly two) or lacks documented medical contraindications to preferred products.

    Denial Risk

    Opioid attestation and prior short-acting trial

    Requests for long‑acting opioids may be denied without a provider attestation that therapy is managed per opioid prescribing guidelines and documentation of an inadequate trial (minimum 30 days) of a short‑acting opioid.

    Denial Risk

    Nexletol/Nexlizet LDL and prior therapy requirement

    Nexletol/Nexlizet requests may be denied if baseline LDL is < 70 mg/dL or if there is no documentation of inadequate response or contraindication to high‑intensity statins and ezetimibe.

    • Baseline LDL ≥ 70 mg/dL and prior statin/ezetimibe failure/contraindication must be documented.
    Denial Risk

    Product withdrawn — not eligible

    Relyvrio has been withdrawn from the market and is not eligible for coverage; PA requests for Relyvrio will be denied.

    Denial Risk

    Allergic reaction to generic required for some products

    Coverage may be denied if documentation does not support a documented allergic reaction to the equivalent generic when that is the reserved PA criterion; providers must include allergy documentation when requested.

    Denial Risk

    Failure of preferred therapies required for some products

    Coverage may be denied if the member has not had an inadequate response to preferred alternatives when the PA states the product is reserved for inadequate response to two preferred alternatives; include trial/failure documentation in the PA.

    Denial Risk

    Common triggers for denial

    Prior authorization denials may be triggered when required documentation—such as specialist management, Pseudomonas infection for inhaled tobramycin products, age or quantity limits, or opioid management attestations—is not provided.

    • Example: inhaled tobramycin requires Pseudomonas documentation and CF center specialist management.
    Denial Risk

    Tramadol ER attestation

    Failure to attest that tramadol ER therapy is being managed per standard opioid prescribing guidelines and to document an adequate prior trial (minimum 30 days continuous use of tramadol IR) may result in denial.

    • Tramadol IR trial minimum: 30 days continuous use.
    Billing Rule

    IR opioid quantity limits

    New users of immediate‑release opioids are limited to a 7‑day supply for the first fill and 14‑day total per episode; longer therapy requires prior authorization with provider attestation and opioid risk assessment documentation.

    • IR opioid new-user limits: 7‑day first fill; 14‑day total per episode.
    Denial Risk

    Failure to meet step requirements

    Requests may be denied if the patient has not had an inadequate response to the required number of preferred alternatives (commonly two) or lacks documented medical contraindication; include trial/failure documentation in the PA.

    Denial Risk

    No documented allergy to generic

    Requests for brand formulations may be denied without documentation of a documented allergic reaction to the equivalent generic when the policy reserves the product for such patients.

    Note
    Note
    Note
    Note

    Initial Therapy / Authorization Rules

    Initial therapy rules (product-specific)

    Initial therapy rules (product‑specific):

    Product-level initial therapy rules: Many products are reserved for patients with inadequate response to one or two preferred products, or for those with documented allergic reaction to equivalent generics; some products require FDA‑approved indication only or reference specific PA PDFs for full criteria.varies by product

    See product‑specific PA links.

    Initial therapy — select opioids

    Initial therapy — select opioids:

    Long-acting opioid initial requirement: Provider attestation that therapy is managed per standard opioid prescribing guidelines AND patient had an inadequate response to a recent adequate trial (>=30 days continuous) of a short‑acting opioid.>=30 days

    Applies to long‑acting opioid products.

    Initial therapy durations

    Initial therapy durations (examples):

    Cystinosis ophthalmics initial: Initial approvals for CYSTADROPS and CYSTARAN will be provided for three months when prescribed by a specialist for cystinosis.3 months initial

    Renewals require documentation of clinical treatment effect.

    Dalfampridine ER initial: Initial approval for six months when MS walking criteria and neurologist attestation are met; dose ≤10 mg twice daily.6 months initial

    Continuation requires documented ambulation improvement.

    Lanreotide initial therapy

    Lanreotide initial therapy:

    Lanreotide initial approval: Reserved for patients for whom surgery is not an option or not curative, and who have failed one somatostatin analogue; initial approvals for six months with annual approvals for responders.failed one somatostatin analogue; initial 6 months

    Per Somatuline Depot entry.

    Initial therapy examples

    Initial therapy examples (selected specialty products):

    Nuzyra initial criteria: Reserved for FDA‑approved indications, prescribing by or in consultation with Infectious Disease providers, and for patients with inadequate response to standard treatments; culture and sensitivity results are required.

    Per Nuzyra entry.

    NUPLAZID initial criteria: Reserved for FDA‑approved indication for Parkinson's disease psychosis and for patients with frequent psychotic symptoms severe enough to warrant antipsychotic treatment; initial approvals for 3 months and continued coverage up to 12 months requires documentation of improvement.3 months initial

    Per NUPLAZID entry.

    Initial authorization patterns

    Initial authorization patterns (general):

    Initial authorization general: Initial approvals for specialty products frequently require demonstration of prior therapy trials or contraindication documentation, specialist management where specified, and product‑specific initial approval durations.product‑specific

    Consult linked PA pages for full product criteria.

    Initial therapy requirements (general)

    Initial therapy requirements (general):

    Initial authorization logic: Authorize when there is documented inadequate response to preferred alternatives or documented contraindication/allergy to preferred/generic products as specified per product; follow product-specific PA documents for required numbers of failures and supporting documentation.

    Per formulary guidance.

    Tramadol initial therapy

    Tramadol initial therapy specifics:

    Tramadol ER initial: Tramadol ER requires provider attestation that therapy is managed per standard opioid prescribing guidelines and documentation of a prior adequate trial (minimum 30 days continuous) of tramadol immediate release; reserved for adults and children ≥ 12 years when specified.30 days

    IR opioid supply limits for new users also apply (7‑day first fill; 14‑day total per episode).

    Continuation / Reauthorization Rules

    Specified continuation rules

    Specified continuation requirements (examples):

    Cystinosis ophthalmics renewal: Renewals require documentation of clinical treatment effect (e.g., slit lamp exam notes) and are provided for up to one year.clinical improvement documented

    Per CYSTADROPS/CYSTARAN entries.

    Dalfampridine ER continuation: Continued approval after initial 6 months requires documented improvement in ambulation; annual approvals thereafter for sustained benefit.documented ambulation improvement

    Per dalfampridine entry.

    Lanreotide continuation therapy

    Lanreotide continuation:

    Annual renewal: Approvals provided annually thereafter for responders with documented clinical benefit.annual

    Requires documented response.

    Continuation therapy examples

    Continuation therapy examples:

    NUPLAZID continuation: Continued coverage for up to 12 months available for patients with medical chart documentation of improvement after initial 3‑month approval.

    Per NUPLAZID entry.

    Nexletol/Nexlizet reauthorization: Approvals given for one year; re‑authorizations require documentation of LDL reduction per provider attestation.

    Per Nexletol/Nexlizet entries.

    Selected continuation rules

    Selected continuation rules (example):

    Reyvow continuation: Initial authorization provided for 6 months; reauthorization provided for 12 months for patients meeting response criteria.initial 6 months then 12-month renewals

    Per Reyvow entry.

    Continuation rules (examples)

    Continuation example (Viberzi):

    Viberzi continuation: One‑year continuations are approved for patients with a significant positive response after the initial approval period; initial approvals limited to one month.

    Per Viberzi entry.

    Step Therapy Tables & Rules

    RequirementDetails
    Members must try preferred alternatives before coverage of non-preferred products
    Step therapy commonly requires trial and inadequate response to one or two preferred products (often two) prior to coverage
    RequirementDetails
    Documented trial and failure of preferred alternatives
    Coverage requires documentation of inadequate response to required preferred agents or documentation of medical contraindication/allergy per product-specific criteria
    RequirementDetails
    Brand use reserved until preferred alternatives fail
    Many branded products are reserved for patients with documented failure/contraindication to preferred alternatives or documented allergy to the equivalent generic
    RequirementDetails
    Trial and failure of two alternatives or prior stability
    Example (Caplyta): tried and failed at least 2 formulary alternatives OR previously stable on the medication
    RequirementDetails
    Prior trials or allergy/contraindication required
    Entries frequently reserve coverage for patients who have tried specified numbers of preferred alternatives or who have documented allergy/contraindication to preferred/generic equivalents
    RequirementDetails
    Trial and documented failure of preferred alternatives
    Multiple products require documented inadequate response to preferred options (commonly two) before non-preferred product will be approved
    RequirementDetails
    Trial and failure required
    Many non-preferred agents require prior trial and inadequate response to preferred alternatives prior to coverage
    RequirementDetails
    Trial and failure or contraindication/allergy
    Coverage contingent on failure of preferred therapies or documentation of allergy/medical contraindication to preferred/generic alternatives
    RequirementDetails
    Two preferred alternative requirement
    Step therapy typically requires trial and inadequate response to two preferred alternatives (or one for some products) before approving non-preferred agents
    RequirementDetails
    Specialty prescriber or lab requirement for some drugs
    Certain products (e.g., inhaled tobramycin) require prescribing/management by specialists and specific documentation (Pseudomonas in lungs) and quantity limits
    RequirementDetails
    Document trials or follow product-specific PA link
    Providers must document prior trials of preferred agents or follow the referenced product-specific prior authorization criteria/links for approval
    RequirementDetails
    Opioid attestation requirement
    Long-acting opioids require provider attestation that therapy is managed per opioid prescribing guidelines and evidence of an adequate recent trial (minimum 30 days continuous) of a short-acting opioid
    RequirementDetails
    Applied broadly to many drugs
    Step therapy rules are applied across many listed products; providers must document prior trials, contraindications, or follow linked PA criteria as specified
    RequirementDetails
    Document prior trials or specialty prescriber
    Coverage may require documentation of prior therapy trials and inadequate response or prescribing by a specialty provider depending on product-specific criteria
    RequirementDetails
    Must document trials/failures or contraindications
    Many products require documentation of failed preferred therapies or documented allergy/contraindication before coverage of non-preferred agents
    RequirementDetails
    Specialist prescription and annual documentation for renewals
    Certain specialty products (e.g., inhaled tobramycin) require specialist management and annual documentation of effectiveness for renewals
    RequirementDetails
    Step through preferred alternatives unless contraindication
    Coverage is reserved until patient has inadequate response to preferred alternatives or a documented medical contraindication/allergy
    RequirementDetails
    Trial and failure of preferred therapies or documented contraindication/allergy
    Providers must document inadequate response to preferred therapies (commonly two) or document medical contraindication/allergy; some products additionally require evidence of clinical benefit or specific tests per linked PA documents

    Clinical Thresholds & Coding Notes

    Parenteral nutrition volume
    Parenteral nutrition volume threshold>= 4L daily
    Required duration of dependence for Gattex initial approvalDependent on parenteral nutrition for at least one year
    Minimum frequency of parenteral nutritionAt least three or more days per week
    LDL cholesterol
    LDL cholesterol threshold for Nexletol/Nexlizet>= 70 mg/dL
    Required prior therapyInadequate response to high-intensity statins (and to ezetimibe) or documented contraindication
    Authorization durationApprovals are given for one year with reauthorization requiring documented LDL reduction
    Short-acting opioid trial duration
    Definition of adequate short-acting opioid trialMinimum of 30 days of continuous use
    PurposeRequired before considering long-acting opioid therapy per provider attestation
    Applies toLong-acting opioid prior authorization entries (e.g., morphine ER, fentanyl)
    Tramadol IR trial duration
    Tramadol IR adequate trial for Tramadol ER PAMinimum 30 days continuous use of tramadol immediate release
    Age restriction noteTramadol reserved for adults and children 12 years and older
    Provider attestationTramadol ER requires provider attestation that therapy is managed per standard opioid prescribing guidelines
    IR opioid new-user supply limit
    New-user IR opioid supply limit — first fill7-day supply
    New-user IR opioid supply limit — episode total14-day total per episode
    Requirement for longer therapyLonger therapy requires prior authorization with provider attestation and risk assessment documentation

    Quantity & Supply Limits

    CAYSTON (aztreonam inhalation)
    Quantity limitOne 28-day package per month
    Clinical eligibilityCystic fibrosis with Pseudomonas aeruginosa in the lungs
    Prescriber/site requirementPrescribed and managed by specialists from a cystic fibrosis treatment center
    TOBRAMYCIN inhalation (300 mg/4 mL & 300 mg/5 mL & PAK)
    Quantity limitOne 56-count carton per 56 days
    Clinical eligibilityUse in cystic fibrosis patients known to have Pseudomonas aeruginosa in the lungs
    Prescriber/site requirementPrescribed and managed by specialists from a cystic fibrosis treatment center; annual documentation required for renewal
    IR Opioids (new users)
    New-user supply limit7-day first fill; 14-day total per episode
    Requirement for continuation or longer therapyPrior authorization with provider attestation that therapy is managed per opioid prescribing guidelines and assessment of risk factors
    Applies toImmediate-release opioid formulations for new users

    Prescribing & Site-of-Care Requirements

    Note
    Note
    Note
    Note

    Background & Rationale

    Step therapy is a utilization management approach that requires members to try specified preferred alternatives before coverage of non‑preferred medications. Prior authorization enforces these requirements by requiring documentation of prior trials, documented contraindications, or other product‑specific criteria before coverage is approved.

    Key Definitions

    Step Therapy (definition)
    Step Therapy (ST)Members must try specified preferred alternative medicines first; approval is required if alternatives have not been tried
    When to request approvalIf alternatives were not tried, provider must request approval for coverage at lower cost share
    PurposeA utilization management approach to reserve non-preferred products for patients with inadequate response or contraindication to preferred agents
    Prior Authorization (definition)
    Prior Authorization (PA)A requirement that certain medicines meet HealthPartners prior authorization criteria in order to be covered by pharmacy benefits
    Consequence of no PALack of PA approval will prevent coverage of the medication
    Where to find criteriaProduct-specific PA requirements and links are provided in the formulary documentation
    Step Therapy (alternate definition)
    Step Therapy (ST)Non-preferred medications are reserved for patients who have had inadequate response to preferred alternatives or have documented contraindications/allergies
    Typical requirementDocumentation of trial and failure of preferred alternatives as specified per product
    VariationSome products require documentation in the medical literature of clinical benefits over preferred alternatives
    adequate trial (definition)
    Adequate trial (opioid-specific)For long-acting opioids, an adequate trial of a short-acting opioid is defined as a minimum of 30 days of continuous use
    Use in PA decisionsProvider attestation of the adequate trial is required for long-acting opioid prior authorization
    Related entriesApplies to long-acting opioid entries such as buprenorphine, morphine ER, fentanyl formulations
    Step Therapy (definition)
    Step Therapy (ST)A formulary management approach where coverage of a non-preferred product is contingent on prior inadequate response or contraindication to one or more preferred alternatives
    Number of required failuresSpecific number of failed preferred alternatives varies by product (commonly one or two)
    ExceptionsSome products permit coverage if patient was previously stable on the non-preferred product
    Reserved for FDA-approved indications (definition)
    Reserved for FDA-approved indicationsCoverage is limited to FDA-approved uses of the drug; may require prior trial/failure of preferred alternatives or documented contraindications
    DocumentationProduct-specific PA documents may specify additional requirements such as specialist prescribing or lab thresholds
    ImplicationUse outside FDA-approved indications would be excluded unless product-specific PA allows it
    Reserved for patients with a documented allergic reaction to the equivalent generic (definition)
    Reserved for patients with documented allergic reaction to equivalent genericBrand-name product coverage is limited to members with documented allergy to the generic equivalent
    Evidence requiredProvider must document the allergic reaction to the generic in the medical record per PA requirements
    Common applicationUsed across many branded entries as the reason to approve brand over generic
    Step Therapy (definition repeat)
    Step Therapy (ST)A utilization management process where patients must try and have an inadequate response to specified preferred alternatives before coverage is provided for a non‑preferred agent
    Follow product criteriaProvider must follow product-specific PA links for exact requirements and number of required failures
    Common enforcementFailure to meet step therapy prerequisites may result in denial of coverage
    Step Therapy (definition repeat 2)
    Step Therapy (ST)Coverage of a non-preferred medication is reserved until the member has an inadequate response to, or contraindication/allergy to, specified preferred alternatives
    Typical number of failuresCommonly requires failure of two preferred alternatives unless otherwise specified
    DocumentationMedical literature documentation may be required for some products claiming superiority
    Step Therapy (definition repeat 3)
    Step Therapy (ST)A coverage approach reserved for FDA-approved indications in which patients must have an inadequate response to two preferred alternatives or have documented medical contraindications to those alternatives
    ApplicabilityApplied broadly across many listed products; product-specific PA pages provide exact criteria
    Common exceptionsDocumented allergy to generic or prior stability on the non-preferred product may permit coverage
    Reserved (definition)
    Reserved (definition)Indicates the product is subject to prior authorization under specified conditions (e.g., documented allergic reaction to generic or inadequate response to preferred alternatives)
    ImplicationRequests outside the reserved conditions will generally be denied absent supporting documentation
    Where detailed rules liveSee linked product-specific PA PDFs/pages for full criteria
    IR Opioids (definition)
    IR Opioids (definition)Immediate-release opioid formulations; new users are limited to a 7-day supply for first fill and a 14-day supply per episode without prior authorization
    Requirement for longer therapyLonger therapy requires prior authorization with provider attestation and opioid risk assessment documentation
    Example productsApplies to tramadol IR and other immediate-release opioid entries referenced in the policy
    Authorized generic (definition)
    Authorized generic (as brand product)A drug marketed as an authorized generic but approved by the FDA as a brand product; PA may be reserved for patients with documented allergic reaction to the equivalent brand/generic
    ImplicationPlan may treat an authorized generic as brand for PA purposes when allergy documented
    Example entriesUMECLIDINIUM and related authorized generic entries referenced in policy
    Step Therapy (definition repeat 4)
    Step Therapy (ST)A utilization management strategy requiring patients to try and fail preferred alternatives (commonly two) before coverage of a non‑preferred product, unless contraindicated
    Provider actionDocument trials of preferred agents or provide documentation of contraindication/allergy; follow linked PA documents for product-specific criteria
    Denial riskRequests may be denied if required step therapy trials are not documented